On September 1, 2020 BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, reported that a member of the senior management team will be presenting at the following virtual conferences (Press release, BerGenBio, SEP 1, 2020, View Source [SID1234564211]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Solebury Trout Zoomside Chat, 1 September 1pm EDT (19:00 CEST)
Live 1-2-1 interview with USA analyst Soumit Roy from Jones Trading.
Registration for attendees.
LSX Nordic Congress, 1-4 September
Presentation available during the conference
Registration for attendees.
Pareto Securities 11th Healthcare Conference, 2-3 September
Presentation on Thursday 3 September, 11:30am CEST
Registration for attendees.
Wainwright’s 22nd Annual Global Investment Conference, 14-16 September
Presentation on Wednesday 16 September, 10:30am EST.
Registration for attendees.
All presentations will be made available on the Company website in the Presentations section on the day of the respective events:
www.bergenbio.com/investors/presentations/
About AXL
AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases. In cancer, AXL suppresses the body’s immune response to tumours and drives cancer treatment failure across many indications. AXL expression defines a very poor prognosis subgroup in most cancers. AXL inhibitors, therefore, have potential high value at the centre of cancer combination therapy, addressing significant unmet medical needs and multiple high-value market opportunities. Research has also shown that AXL mediates other aggressive diseases.
About Bemcentinib
Bemcentinib (formerly known as BGB324), is a potentially first-in-class selective AXL inhibitor in a broad phase II clinical development programme. Ongoing clinical trials are investigating bemcentinib in multiple solid and haematological tumours, in combination with current and emerging therapies (including immunotherapies, targeted therapies and chemotherapy), and as a single agent. Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumour cells, leading to aggressive metastatic cancers.